​

Penumbra (PEN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PEN Stock Forecast

Penumbra (PEN) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $284.83, with a high of $325.00 and a low of $235.00. This represents a -4.07% decline from the last price of $296.91.

$150 $190 $230 $270 $310 $350 High: $325 Avg: $284.83 Low: $235 Last Closed Price: $296.91

PEN Stock Rating

Penumbra stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (78.95%), 4 Hold (21.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 4 15 Strong Sell Sell Hold Buy Strong Buy

PEN Price Target Upside V Benchmarks

TypeNameUpside
StockPenumbra-4.07%
SectorHealthcare Stocks 30.37%
IndustryMedical Device Stocks19.97%

Price Target Trends

1M3M12M
# Anlaysts3320
Avg Price Target$319.33$319.33$236.40
Last Closing Price$296.91$296.91$296.91
Upside/Downside7.55%7.55%-20.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252134--19
Mar, 252124--18
Feb, 252124--18
Jan, 252124--18
Dec, 243115--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2025David RescottRobert W. Baird$325.00$298.258.97%9.46%
Apr 24, 2025Mathew BlackmanStifel Nicolaus$318.00$277.0414.78%7.10%
Apr 15, 2025Shagun SinghRBC Capital$315.00$272.3215.67%6.09%
Dec 11, 2024Larry BiegelsenWells Fargo$275.00$253.668.41%-7.38%
Oct 31, 2024Matt O'BrienPiper Sandler$235.00$211.2911.22%-20.85%
Oct 31, 2024Pito ChickeringDeutsche Bank$241.00$211.2914.06%-18.83%
Oct 18, 2024Matt O'BrienPiper Sandler$225.00$202.2611.24%-24.22%
Oct 16, 2024Jason MillsCanaccord Genuity$235.00$206.6213.74%-20.85%
Oct 15, 2024David RescottRobert W. Baird$244.00$211.3615.44%-17.82%
Oct 14, 2024Richard NewitterTruist Financial$235.00$214.929.34%-20.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 24, 2025UBSBuyBuyhold
Apr 15, 2025RBC CapitalOutperformOutperformhold
Dec 11, 2024Wells FargoEqual-WeightOverweightupgrade
Oct 31, 2024RBC CapitalOutperformOutperformhold
Oct 31, 2024Deutsche BankBuyBuyhold
Oct 18, 2024Piper SandlerOverweightOverweighthold
Oct 16, 2024Canaccord GenuityBuyBuyhold
Oct 15, 2024Wells FargoEqual-WeightEqual-Weighthold
Oct 14, 2024BTIGBuyBuyhold
Oct 08, 2024RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.54$0.07$-0.05$2.37$0.36----
Avg Forecast$-0.18$0.81$0.15$2.03$2.79$3.80$4.96$6.32$7.56
High Forecast$-0.17$0.83$0.16$2.20$2.97$4.37$5.83$6.87$7.72
Low Forecast$-0.18$0.80$0.15$1.90$2.68$3.49$4.46$5.76$7.35
Surprise %200.00%-91.36%-133.33%16.75%-87.10%----

Revenue Forecast

$500M $900M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$560.41M$747.59M$847.13M$1.06B$1.19B----
Avg Forecast$548.91M$738.09M$843.69M$1.06B$1.19B$1.36B$1.56B$1.76B$1.98B
High Forecast$560.31M$753.42M$854.36M$1.08B$1.20B$1.38B$1.56B$1.77B$2.01B
Low Forecast$541.38M$727.97M$829.90M$1.04B$1.17B$1.34B$1.56B$1.75B$1.93B
Surprise %2.10%1.29%0.41%-0.20%0.33%----

Net Income Forecast

$-50M $30M $110M $190M $270M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.26M$2.62M$-2.00M$90.95M$14.01M----
Avg Forecast$-8.11M$-4.05M$-34.15M$90.95M$110.92M$146.01M$192.40M$260.55M$296.48M
High Forecast$4.89M$8.84M$-22.81M$120.73M$116.57M$171.28M$228.83M$269.26M$302.75M
Low Forecast$-21.10M$-16.95M$-45.49M$61.17M$105.26M$136.95M$175.08M$226.04M$288.28M
Surprise %137.52%-164.72%-94.14%--87.37%----

PEN Forecast FAQ

Is Penumbra stock a buy?

Penumbra stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Penumbra is a favorable investment for most analysts.

What is Penumbra's price target?

Penumbra's price target, set by 19 Wall Street analysts, averages $284.83 over the next 12 months. The price target range spans from $235 at the low end to $325 at the high end, suggesting a potential -4.07% change from the previous closing price of $296.91.

How does Penumbra stock forecast compare to its benchmarks?

Penumbra's stock forecast shows a -4.07% downside, underperforming the average forecast for the healthcare stocks sector (30.37%) and underperforming the medical device stocks industry (19.97%).

What is the breakdown of analyst ratings for Penumbra over the past three months?

  • April 2025: 10.53% Strong Buy, 68.42% Buy, 21.05% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Penumbra’s EPS forecast?

Penumbra's average annual EPS forecast for its fiscal year ending in December 2025 is $3.8, marking a 955.56% increase from the reported $0.36 in 2024. Estimates for the following years are $4.96 in 2026, $6.32 in 2027, and $7.56 in 2028.

What is Penumbra’s revenue forecast?

Penumbra's average annual revenue forecast for its fiscal year ending in December 2025 is $1.36B, reflecting a 13.98% increase from the reported $1.19B in 2024. The forecast for 2026 is $1.56B, followed by $1.76B for 2027, and $1.98B for 2028.

What is Penumbra’s net income forecast?

Penumbra's net income forecast for the fiscal year ending in December 2025 stands at $146.01M, representing an 942.01% increase from the reported $14.01M in 2024. Projections indicate $192.4M in 2026, $260.55M in 2027, and $296.48M in 2028.